Canada's Research-Based Pharmaceutical Companies (Rx&D)

Canada's Research-Based Pharmaceutical Companies (Rx&D)

November 20, 2014 10:12 ET

Notice of Nomination: John Helou

TORONTO, ONTARIO--(Marketwired - Nov. 20, 2014) - Canada's Research-Based Pharmaceutical Companies is pleased to announce the appointment of John Helou, President, Pfizer Canada Inc. as Chair of the Association's Board of Directors for 2014-2015. Mr. Helou assumed the role during the Association's Annual General meeting held in Toronto on November 20, 2014.

Mr. Helou has been an industry leader for over 24 years. He has served as a member of the Association's Board of Directors, Executive Committee and Chair of several committees.

Mr. Helou has been President of Pfizer Canada Inc. since January 2012 and serves as General Manager of the Global Innovative Pharma Business for Canada. Prior to this, he managed Pfizer's Specialty Care Business in Canada and Puerto Rico.

Mr. Helou is actively involved in several industry, business and community associations. He is an Executive Committee Member and Vice-Chair of BIOTECanada, a Board Member of Montreal InVivo and the Advanced Coronary Treatment (ACT) Foundation. In addition, Mr. Helou is a member of the Council of Canadian Chief Executives and a member of the Deans Advisory Board and Campaign Cabinet at the University of Toronto, Faculty of Pharmacy. Mr. Helou holds a chemical engineering degree from the University of Toronto.

About Canada's Research-Based Pharmaceutical Companies

Canada's Research-Based Pharmaceutical Companies is the national association representing the voice of Canada's innovative pharmaceutical industry. We serve our membership by advocating for policies that enable the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. We support our memberships' commitment to being a valued partner in the Canadian healthcare system. We represent more than 50 companies investing over $1-billion in R&D annually, fuelling Canada's knowledge-based economy, while contributing over $3-billion overall to Canada's economy. Guided by our Code of Ethical Practices, we work with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.

Contact Information